NEW YORK (GenomeWeb) – Vermillion today said it has received US Food and Drug Administration 510(k) clearance for its Overa ovarian cancer test.

The test is a second-generation version of the company's OVA1 test, and like OVA1 is intended to aid clinicians in assessing whether a pelvic mass slated for surgery is likely malignant or benign. In the case of likely malignant masses, patients can then be passed on for surgery to a gynecologic oncologist, as opposed to having the surgery done by their regular Ob/Gyn.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.

Oct
10
Sponsored by
PerkinElmer

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.